Your browser doesn't support javascript.
loading
SMAC Mimetic Debio 1143 and Ablative Radiation Therapy Synergize to Enhance Antitumor Immunity against Lung Cancer.
Tao, Zhen; McCall, Neal S; Wiedemann, Norbert; Vuagniaux, Grégoire; Yuan, Zhiyong; Lu, Bo.
Afiliación
  • Tao Z; Department of Radiation Oncology and Cyberknife Center, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
  • McCall NS; Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania.
  • Wiedemann N; Debiopharm International SA, Lausanne, Switzerland.
  • Vuagniaux G; Debiopharm International SA, Lausanne, Switzerland.
  • Yuan Z; Department of Radiation Oncology and Cyberknife Center, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China. bo.lu@jefferson.edu zhiyong0524@163.com.
  • Lu B; Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania. bo.lu@jefferson.edu zhiyong0524@163.com.
Clin Cancer Res ; 25(3): 1113-1124, 2019 02 01.
Article en En | MEDLINE | ID: mdl-30352911
PURPOSE: Adaptive antitumor immunity following ablative radiotherapy (ART) is attenuated by host myeloid-derived suppressor cell (MDSC), tumor-associated macrophage (TAM), and regulatory T-cell (Treg) infiltrates. We hypothesized treatment with ART and a secondary mitochondrial-derived activators of caspase (SMAC) mimetic could reverse the immunosuppressive lung cancer microenvironment to favor adaptive immunity. EXPERIMENTAL DESIGN: To evaluate for synergy between ART and the SMAC mimetic Debio 1143 and the dependence upon CD8+ T cells and TNFα, we used LLC-OVA syngeneic mouse model of lung cancer and treated them with Debio 1143 and/or ART (30 Gy) with or without anti-CD8, anti-TNFα, or anti-IFNγ antibodies. Tumor-infiltrating OVA-specific CD8+ T cells, Tc1 effector cells, MDSCs, TAMs, and Tregs, were quantified by flow cytometry. Tc1-promoting cytokines TNFα, IFNγ, and IL1ß and the immunosuppressive IL10 and Arg-1 within LLC-OVA tumor tissue or mouse serum were measured by RT-PCR and ELISA. RESULTS: ART delayed tumor growth, and the addition of Debio 1143 greatly enhanced its efficacy, which included several complete responses. These complete responders rejected an LLC-OVA tumor rechallenge. ART and Debio 1143 synergistically induced a tumor-specific, Tc1 cellular and cytokine response while eliminating immunosuppressive cells and cytokines from the tumor microenvironment. Depletion of CD8+ cells, TNFα, and IFNγ with blocking antibody abrogated synergy between ART and Debio 1143 and partially restored tumor-infiltrating MDSCs. CONCLUSIONS: Debio 1143 augments the tumor-specific adaptive immunity induced by ART, while reversing host immunosuppressive cell infiltrates in the tumor microenvironment in a TNFα, IFNγ, and CD8+ T-cell-dependent manner. This provides a novel strategy to enhance the immunogenicity of ART.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Radioterapia / Azocinas / Compuestos de Bencidrilo / Carcinoma Pulmonar de Lewis / Proteínas Mitocondriales / Materiales Biomiméticos / Proteínas Reguladoras de la Apoptosis / Neoplasias Pulmonares Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2019 Tipo del documento: Article País de afiliación: China Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Radioterapia / Azocinas / Compuestos de Bencidrilo / Carcinoma Pulmonar de Lewis / Proteínas Mitocondriales / Materiales Biomiméticos / Proteínas Reguladoras de la Apoptosis / Neoplasias Pulmonares Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2019 Tipo del documento: Article País de afiliación: China Pais de publicación: Estados Unidos